Inventor · disambiguated record
Adam Castoreno
Also filed as: CASTORENO ADAM
18 granted patents·42 pending applications·17 citations·filing 2019–2024
90Inventor score
Files withALNYLAM PHARMACEUTICALS INC60
Top patents by PatentIndex Score
60 records- 0194US11326166B1Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted May 10, 2022·3 cites·29 claims
- 0294US11149276B2Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Oct 19, 2021·4 cites·30 claims
- 0393US11926832B2Ketohexokinase (KHK) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Mar 12, 2024·4 cites·30 claims
- 0492US11959081B2Transthyretin (TTR) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 16, 2024·1 cites·30 claims
- 0591US11965166B2Complement factor B (CFB) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Apr 23, 2024·1 cites·30 claims
- 0690US11993774B2Huntingtin (HTT) iRNA agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted May 28, 2024·1 cites·30 claims
- 0788US12049630B2Factor XII (F12) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Jul 30, 2024·1 cites·30 claims
- 0884US11162103B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Nov 2, 2021·1 cites·23 claims
- 0983US12005074B2Extrahepatic deliveryALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Jun 11, 2024·0 cites·28 claims
- 1083US2024358738A1Extrahepatic deliveryALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1182US12258565B2Complement component C3 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Mar 25, 2025·0 cites·28 claims
- 1282US11034957B2Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Jun 15, 2021·1 cites·30 claims
- 1381US12404508B2Ketohexokinase (KHK) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Sep 2, 2025·0 cites·29 claims
- 1477US2024409929A1Transthyretin (ttr) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1576US2025059536A1Tunable reversir tm compoundsALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1675US12416006B2Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Sep 16, 2025·0 cites·23 claims
- 1775US2025115911A1Snca-targeting sirna compositions for treating snca-associated diseaseALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1875US2025027080A1Complement factor b (cfb) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1975US2024368594A1Huntingtin (htt) irna agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2074US12365896B2Complement component C3 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Jul 22, 2025·0 cites·52 claims
- 2174US2025059541A1Snca-targeting sirna compositions for treating snca-associated diseaseALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2273US12018260B2Tunable Reversir™ compoundsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Jun 25, 2024·0 cites·19 claims
- 2373US11649459B2Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseasesALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted May 16, 2023·0 cites·30 claims
- 2473US2025084418A1Compositions and methods for silencing carbonic anhydrase 2 expressionALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2572US2024150767A1SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASESALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2672US2024401056A1FACTOR XII (F12) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2770US12397013B2Extrahepatic deliveryALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Aug 26, 2025·0 cites·66 claims
- 2870US2025011776A1Huntingtin (htt) irna agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2969US2024318184A1PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3067US2022411801A1XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3166US12480125B2Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Nov 25, 2025·0 cites·20 claims
- 3266US2023392156A1G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3366US2024124882A1Prion protein (prnp) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3466US2024392294A1Irna compositions and methods for silencing angiotensinogen (agt)ALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3565US2024254493A1Compositions and methods for silencing carbonic anhydrase 2 expressionALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3665US2024132895A1GLYCOGEN SYNTHASE KINASE 3 ALPHA (GSK3 ALPHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3765US2025034567A1Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3863US2023193268A1APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3963US2022002724A1AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4063US2024018515A1Complement factor b (cfb) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4162US2023416736A1Mucin 5b (muc5b) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4261US2024200077A1Stearoyl-coa desaturase 5 (scd5) irna agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4361US2024301418A1iRNA Compositions and Methods for Silencing Filamin A (FLNA)ALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4460US2024318175A1Compositions and Methods for Silencing MYOC ExpressionALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4558US2024409943A1iRNA Compositions and Methods for Targeting ANGPTL7ALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4658US2024209373A1ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4757US2024011032A1Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseasesALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4857US2023159933A1Compositions and methods for silencing scn9a expressionALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4956US2025051767A1iRNA Compositions and Methods for Silencing MYLIPALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 5055US2025283071A1Modified double stranded oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 60 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Adam Castoreno files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →